Anheuser-Busch InBev SA/NV (0A22)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 84.26 |
|---|---|
| 52-week range | 59.74 – 86.93 |
| Return, 1 month / 3 months | +9.8% / +5.3% |
| Return, 1 year / 3 years | +39.2% / +64.8% |
| Trend | Uptrend |
| RSI (14) | 66 |
| Volatility (1 year) | 24.9% |
| Worst drawdown (1 year) | -16.5% |
| Average daily value traded | 1.96M USD |
| Dividend yield | 1.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Anheuser-Busch InBev is a brewer based in Leuven, Belgium, with brewing and distribution operations across the Americas, Europe, Africa and Asia. The company makes and markets beer and other malt beverages through a portfolio of brands that includes Budweiser, Stella Artois, Corona and Beck's, alongside many local and regional labels. Its customers are retailers, wholesalers, bars, restaurants and other outlets that serve consumers, and it also produces some non-alcoholic beverages.
The shares are listed on the London Exchange in UK under the code 0A22, and the price on this page is in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Anheuser-Busch InBev SA/NV (0A22) trades on the London Exchange in UK. It last closed at USD 84.26 on 23 October 2026.
Its price-based Market X-Ray is 69 out of 100 (a fair price profile), ranking 614 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 39.2% and over the last three months it rose 5.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 73 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 8.9% | ||
| From 52-week high | -1.7% | ||
| Momentum | 75 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 5.3% | ||
| 6-month return | 18.0% | ||
| 12-month return, skipping the last month | 26.9% | ||
| Stability (higher is calmer) | 79 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 24.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.5% | ||
| Liquidity | 60 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.96M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 32 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.4% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.1% |
|---|---|
| 1 month | +9.8% |
| 3 months | +5.3% |
| 6 months | +18.0% |
| 1 year | +39.2% |
| 3 years | +64.8% |
| 5 years | +57.9% |
Signals
| 50-day / 200-day average | 78.60 / 77.35 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.57 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 8 May 2026 | EUR 0.8726 |
| 19 Nov 2025 | EUR 0.1722 |
| 7 May 2025 | EUR 1.1282 |
| 3 May 2024 | EUR 0.8802 |
| 3 May 2023 | EUR 0.8232 |
| 3 May 2022 | EUR 0.5276 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.